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Abstract
We report a genome-wide RNA interference (RNAi) screen for Suppressors of Clozapine-induced Larval Arrest (scla genes) in
Caenorhabditis elegans, the first genetic suppressor screen for antipsychotic drug (APD) targets in an animal. The screen
identifies 40 suppressors, including the a-like nicotinic acetylcholine receptor (nAChR) homolog acr-7. We validate the
requirement for acr-7 by showing that acr-7 knockout suppresses clozapine-induced larval arrest and that expression of a
full-length translational GFP fusion construct rescues this phenotype. nAChR agonists phenocopy the developmental effects
of clozapine, while nAChR antagonists partially block these effects. ACR-7 is strongly expressed in the pharynx, and
clozapine inhibits pharyngeal pumping. acr-7 knockout and nAChR antagonists suppress clozapine-induced inhibition of
pharyngeal pumping. These findings suggest that clozapine activates ACR-7 channels in pharyngeal muscle, leading to
tetanus of pharyngeal muscle with consequent larval arrest. No APDs are known to activate nAChRs, but a number of
studies indicate that a7-nAChR agonists may prove effective for the treatment of psychosis. a-like nAChR signaling is a
mechanism through which clozapine may produce its therapeutic and/or toxic effects in humans, a hypothesis that could
be tested following identification of the mammalian ortholog of C. elegans acr-7.
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Introduction
Treatment of psychotic disorders has been hampered by the
limited efficacy of currently available APDs and the toxic side
effects of these drugs [1]. Clozapine is the most effective
medication for treatment-refractory schizophrenia but produces
toxic side effects such as agranulocytosis, metabolic syndrome, and
developmental defects after exposure early in life [2–4]. The
molecular mechanisms underlying the therapeutic and toxic side
effects of clozapine and other APDs remain poorly understood
[5,6]. A better understanding of these mechanisms could facilitate
the design of superior drugs and may inform our understanding,
not only of drug mechanisms, but also of disease pathogenesis. For
example, studies of antidepressant drug mechanisms have
produced new insight into the important role of neurogenesis in
depression itself [7,8].
The genetic tools of invertebrate models offer new paradigms
for drug discovery in schizophrenia [9,10]. Pharmacogenetic
experiments in Caenorhabditis elegans identify novel and important
signal transduction pathways through which APDs exert their
biological effects [11–14]. Large-scale genetic screens in C. elegans
provide an unbiased approach to discover genetic targets of APDs,
and such experiments are not possible in knockout or transgenic
mice. Using such an unbiased approach, we identified a potential
APD target with homology to human brain receptors.
We found that loss-of-function mutations in acr-7, which
encodes a homolog of the human a-like nAChRs, suppressed
both developmental and behavioral effects of clozapine. Our
results indicated that clozapine likely activated the ACR-7
receptor, a novel observation that may be relevant to clinical
drug effects. No known APDs have been previously demonstrated
to activate nAChRs, and whether APDs might act by this
mechanism is an important question. Recent studies in humans
have underscored the potential importance of nAChRs in the
pathophysiology of schizophrenia owing to: (1) the abnormal
expression of nAChRs in post-mortem brains of schizophrenic
patients; (2) the striking association between smoking (a nicotine
delivery system) and schizophrenia; (3) the improved cognition
seen in animals and humans with nicotine exposure; (4) the genetic
association between the human a7-nAChR and schizophrenia;
and (5) the potential efficacy of nAChR agonists as treatments for
schizophrenia [15–17].
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A chemical genetic screen for APD targets
To identify novel molecular mechanisms of action of APDs, we
conducted a genetic suppressor screen for APD targets in an
animal [18]. APDs cause larval arrest or developmental delay in C.
elegans (Figure 1B). APDs inhibit pharyngeal pumping [12,19,20],
indicating that the developmental phenotype has a neuromuscular
basis. To identify potential APD targets, we performed a genome-
wide RNAi screen for Suppressors of Clozapine-induced Larval
Arrest (scla genes). Mutants that escaped clozapine-induced larval
arrest grew to adulthood and were easily detected under a
dissecting microscope (Figure 1B, [21]). The experimental design
is outlined in Figure 1A and involved a primary RNAi screen in
liquid culture followed by triplicate testing in agar wells. To ensure
adequate knockdown of potential targets, we exposed animals to
two rounds of RNAi and tested progeny in the second generation.
We also employed the NL4256 rrf-3(pk1426) II strain, which is
hypersensitive to RNAi and which improves detection of genes
with postembryonic mutant phenotypes, to maximize recovery of
neuronal genes [22].
Of the 19,968 wells we tested in the primary screen, 1,375 wells
or 6.9% displayed suppression of clozapine-induced larval arrest.
magi-1, a membrane-associated guanylate kinase gene, and sec-8 ,
an exocyst complex gene, were each identified as positives twice in
the primary screen. Subsequent testing of primary screen positives
in triplicate identified 40 candidate suppressors, constituting 0.2%
of the total wells screened (Table 1). To rule out false positives, we
collected viable knockout mutants corresponding to our RNAi
suppressors and tested them for suppression of clozapine-induced
larval arrest. These knockouts included strains acr-7(tm863), cep-
1(ep347), cep-1(gk138), cep-1(lg12501), gtl-2(n2618), gtl-2(tm1463),
ina-1(gm39), ins-22(ok3616), lron-6(ok1119), magi-1(gk657), puf-
6(ok3044), scla-1(tm4534), scla-1(tm4806), and sms-1(ok2399).
Suppression of clozapine-induced larval arrest was seen in 70%
of the RNAi screen positives when tested by knockout rather than
by RNAi knockdown, including acr-7, gtl-2, ina-1, magi-1, puf-6,
sms-1, and scla-1. The cep-1, ins-22, and lron-6 knockout strains
failed to suppress clozapine-induced larval arrest, suggesting that
these suppressors were false positives. Alternatively, suppression
may occur in these three cases with partial loss-of-function by
RNAi knockdown, but not with complete loss-of-function by
knockout.
Chemicals such as paraquat are commonly used to study the
genetics of stressor-induced developmental delay or lethality in C.
elegans. We asked whether genes recovered in our RNAi screen
suppress the effects of stressors, including paraquat, DTT, SDS,
and tunicamycin [23–26]. Tunicamycin up to 10 mg/ml and DTT
at 5 mM produced no or mild developmental delay in N2 animals
(data not shown). More robust effects were seen with 0.01% SDS
or 0.2–0.5 mM paraquat (Figure S1). Developmental delay in N2
animals was compared with that in sms-1(ok2399), age-1(hx546),
scla-1(tm4806), scla-1(tm4534), and acr-7(tm863) mutant strains.
None of these mutant strains grew more rapidly in the presence of
SDS or paraquat than N2 animals, suggesting that these mutations
did not act by suppressing stressor effects (Figure S1). Rather, the
suppression seen with these mutations appeared to be specific for
the developmental effects of clozapine. Stressor-induced lethality
was also scored, and, similar to the results of the developmental
delay assay, no suppression was seen with these mutations (data
not shown).
The functional classes of the suppressors revealed that a more
diverse group of genes was required for the biological effects of
clozapine than had been previously appreciated. A fraction of
these genes likely suppressed clozapine-induced larval arrest via
indirect effects. However, molecules involved in signal transduc-
tion significantly outnumbered those in other functional classes,
consistent with the idea that clozapine’s developmental effects
have a neuromuscular basis (Figure 2, [12,19]). Moreover, the
fraction of signal transduction genes from our RNAi screen was
higher than that from a screen for all genes with RNAi phenotypes
in C. elegans [27]. This difference indicated that our dataset was
specific to the effects of clozapine.
acr-7 sequence and homology
We sought to understand the molecular mechanisms of action of
the RNAi suppressors in detail and chose to focus initially on acr-7.
The rationale for focusing on acr-7, as opposed to other new
candidate APD targets, included potential relevance to psychotic
disorders [15–17], probability of a human ortholog [28,29], and
potential for physiological characterization [30]. Blasting the
ACR-7 protein sequence against the human genome using
Wormbase BLAT revealed that ACR-7 is homologous to a
number of human a-like nAChRs, but which human gene is the
true acr-7 ortholog is not known. Homology comparisons with the
human a7-nAChR showed 36% identity overall and greater
identity within the first two predicted transmembrane domains of
the ion channel (Figure 3A). The pore-lining transmembrane
domain II (M2) and neighboring residues play an important role in
the ion selectivity filter of nAChRs. Specifically, substitution of the
glutamate residue immediately preceding M2 or the glutamate
residue at the extracellular mouth of the pore significantly reduces
the calcium permeability of various nAChR subunits [31]. We
noted that both glutamate residues are conserved in ACR-7,
suggesting that, like the human a7-nAChR, ACR-7 is highly
permeable to calcium. Our attempts to obtain voltage-clamp
recordings of ACR-7 expressed in heterologous systems, including
Xenopus laevis oocytes and cultured HEK293T and PC12 cells,
Author Summary
Clozapine is the most effective medication for treatment-
refractory schizophrenia but produces toxic side effects
such as agranulocytosis, metabolic syndrome, and devel-
opmental defects after exposure early in life. However,
clozapine’s molecular mechanisms of action remain poorly
understood. In past studies, we showed that pharmaco-
genomic experiments in C. elegans identify novel signaling
pathways through which clozapine exerts its biological
effects. Here, we report the first genetic suppressor screen
for antipsychotic (APD) drug targets in an animal and
identify 40 suppressors of clozapine-induced larval arrest,
including the a-like nicotinic acetylcholine receptor
(nAChR) acr-7. We validate our RNAi result by showing
that an acr-7 knockout suppresses clozapine-induced larval
arrest and inhibition of pharyngeal pumping. Expression of
a full-length translational acr-7::GFP (Green Fluorescent
Protein) construct in the acr-7 mutant rescues suppression
of these phenotypes. Clozapine-induced phenotypes are
phenocopied by nAChR agonists and blocked by nAChR
antagonists. The results suggest that clozapine induces
these phenotypes through activation of the ACR-7
receptor. Recent studies have underscored the potential
importance of nAChRs in the pathophysiology of schizo-
phrenia. A clearer understanding of APD mechanisms
would facilitate the design of improved drugs and may
inform our understanding, not only of drug mechanisms,
but also of disease pathogenesis.
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heteromeric channel [32,33].
Knockout of acr-7 suppressed clozapine-induced larval
arrest
We tested growth effects over a range of clozapine concentra-
tions (40–320 mM). N2 animals grown in the presence of 0.1%
DMSO alone reached adulthood in ,3 days (Figure 1B and
Figure 4A). Consistent with our previous study [12], clozapine
inhibited the development of N2 animals in a dose-dependent
fashion. For example, 98% of control animals were gravid adults
on day 3, compared to 36% on 80 mM clozapine and 0% on
320 mM clozapine (Figure 1B and Figure 4A).
The acr-7(tm863) allele is a 625 bp out-of-frame deletion with a
7 bp insertion, which removes exons 6–7 and most of exons 5 and
8 (Figure 3B) and lacks all four transmembrane domains
(Figure 3C). Therefore, acr-7(tm863) is predicted to be a null
allele. We backcrossed the acr-7(tm863) allele to the wild-type strain
six times to generate the strain EAB200, which, like animals
exposed to acr-7(RNAi) (Figure 1B), displayed normal development
and normal adult morphology. On 320 mM clozapine, 95% of acr-
7(tm863) mutant animals reached the L4 and young adult (YA)
stages by day 3, compared to 0% of N2 animals (Figure 1B and
Figure 4A). Therefore, acr-7(tm863) partially suppressed clozapine-
induced developmental delay, confirming the knockdown results
from our RNAi screen. Transgenic strain acr-7(tm863) II mchEx40,
which expresses a full-length translational Pacr-7::acr-7::GFP (Green
Fluorescent Protein) fusion construct, was rescued for the Scla
phenotype. On 320 mM clozapine, 100% of these transgenic
animals were arrested at early larval stages (L1, L2, and L3) on day
3, comparable to the delay seen in N2 animals (Figure 4A). We
investigated the specificity of acr-7(lf) suppression by testing
mutations in 21 other C. elegans nAChR subunits and found that
only acr-7(lf) suppressed clozapine-induced developmental delay
(Figure 5).
Developmental effects of nAChR agonists and
antagonists
To determine the mechanism of action of clozapine, we tested
the nAChR agonists nicotine and levamisole [29] and found that
they inhibited growth in a dose-dependent fashion, phenocopying
the effects of clozapine. Only 3% of N2 animals grew to young
adults or beyond by day 3 on 1 mM nicotine, compared to 100%
of control animals (Figure 4B). On 10 mM levamisole, all N2
animals were arrested at the L1–L2 stages on day 3 (Figure 4B).
Similar to its suppression of clozapine-induced developmental
delay, the acr-7(tm863) mutation suppressed nicotine-induced
developmental delay (Figure 4C). This suppression was partially
rescued in acr-7(tm863) II mchEx40 animals (Figure 4C). We also
found that clozapine-induced larval arrest was blocked by the
nAChR antagonists d-tubocurarine (d-TC) and dihydro-beta-
erythroidine (DHbE) [29]. In 320 mM clozapine alone, 96% of N2
animals were arrested at the L1–L2 stages on day 3, compared to
25% in the presence of 500 mM d-TC and 41% in the presence of
500 mMD H bE (Figure 4D). N2 animals displayed normal
development in the presence of d-TC or DHbE alone, consistent
with the normal development seen with acr-7 knockdown or
knockout (Figure 4D). Taken as a whole, our results were
consistent with the notion that acr-7 encodes a nAChR and that
clozapine activates ACR-7. Suppression of the developmental
Figure 1. A genome-wide RNAi screen for scla genes yielded the nAChR gene acr-7. (A) Experimental design of the feeding RNAi screen in
liquid culture. On day 1, rrf-3 animals were synchronized, and bacteria was cultured from the Ahringer RNAi feeding library. Synchronized L1 animals
were added to induced cultures on day 2 and were allowed to grow to adulthood for 3 days. Clozapine was added on day 5, and progeny were
allowed to develop for 3 days. Progeny were scored for the Scla phenotype on day 8. (B1) N2 animals grew to adulthood within 3 days in the
presence of 0.1% DMSO alone. (B2) 320 mM clozapine caused larval arrest in N2 animals exposed to feeding RNAi bacteria with empty vector alone.
(B3) acr-7(RNAi) animals in 0.1% DMSO alone displayed normal development. (B4) acr-7(RNAi) suppressed developmental delay caused by 320 mM
clozapine. (B5) The acr-7(tm863) knockout suppressed developmental delay caused by 320 mM clozapine. Note that experiments depicted in (B) were
performed on NGM plates, not in liquid culture, to allow clear photographs.
doi:10.1371/journal.pgen.1003313.g001
C. elegans ACR-7 and Antipsychotic Drug Effects
PLOS Genetics | www.plosgenetics.org 3 February 2013 | Volume 9 | Issue 2 | e1003313Table 1. Summary of scla genes recovered in genome-wide RNAi screen.
Sequence
Name Locus Functional Group Brief Description Score Hs Mm Dm Sc
C02F12.3 snet-1 Unknown Novel protein +
C05E4.6 str-134 Signal transduction 7-transmembrane receptor ++ OR1-11
C14C6.8 Unknown Extracellular protein with conserved
cysteines
+++ CG12910
C30H7.2 Metabolism Thioredoxin + TXNDC4 Txndc4 CG9911 PDI1
C42C1.1 sre-14 Signal transduction G protein-coupled 7-transmembrane
receptor
+
F01G4.2 ard-1 Metabolism Short chain dehydrogenase ++ HSD17B10 Hsd17b10 scu YDL114W
F07A11.1 Cell structure Trichohyalin NA TCHH Gigyf2
F12F6.3 rib-1 Cell surface Exostosin-like protein + EXT1 Ext1 ttv
F18A11.1 puf-6 Protein synthesis Pumilio family RNA binding protein + PUM1 Pum1 PUF3
F22B3.8 scla-1 Signal transduction Tyrosine kinase +++ ITK Srms Fps85D CDC15
F36H1.1 fkb-1 Protein turnover FK506-binding protein ++ FKBP2 Fkbp2 CG14715 FPR2
F37E3.2 lron-6 Protein-protein interactionLeucine-rich repeat protein NA CPN2 Lrrc15 CG16974 CYR1
F38H4.3 RNA processing Nucleolar phosphoprotein ++ NOLC1 SRP40
F52B5.5 cep-1 Transcription factor p53-like protein +
F52C6.4 Protein turnover Ubiquitin-like protein + UBA52 Ubi-p5E UBI4
F54D1.5 gtl-2 Signal transduction TRP calcium channel ++ TRPM3 Trpm3 CG34123
F54F11.3 sre-45 Signal transduction G protein-coupled 7-transmembrane
receptor
NA
F54G8.3 ina-1 Signal transduction Alpha integrin subunit + ITGA6 Itga6 mew
H21P03.3 sms-1 Metabolism Sphingomyelin synthase +++ SGMS2 Sgms2 SMSr
K01A6.2 magi-1 Signal transduction MAGI/S-SCAM family protein ++ MAGI3 Magi1 Magi MAGI
K07C6.6 srx-63 Signal transduction G protein-coupled 7-transmembrane
receptor
+
K10B2.5 ani-2 Cell structure Actin-binding protein Anillin + ANLN Anln scra
M04D8.2 ins-22 Signal transduction Type-alpha insulin-like peptide +
R09H10.2 Metabolism Small molecule methylase +
R107.8 lin-12 Signal transduction Notch receptor NA NOTCH3 Notch3 N AKR1
T02E1.6 Unknown Novel protein ++
T05F1.2 Unknown Novel protein ++
T09A5.3 acr-7 Signal transduction Alpha-7 nicotinic acetylcholine
receptor
++ CHRNA7 Chrna7 nAcRalpha-34E
T09E11.5 oac-44 Metabolism Acyltransferase +++
T21B4.7 srh-69 Signal transduction G protein-coupled 7-transmembrane
receptor
NA
T22C8.3 Transcription factor C2H2-type zinc-finger protein NA
T26E3.5 Protein-protein interactionF-box protein NA
W03F8.2 Signal transduction Tyrosine kinase FER NA FER Fer CG8874 MKK2
W09G10.5 clec-126 Cell surface C-type lectin + CLEC4M Clec4g
Y48A6B.5 exos-1 RNA processing Exosomal subunit NA EXOSC1 Exosc1 Csl4 CSL4
Y106G6H.7 sec-8 Signal transduction Exocyst complex subunit + EXOC4 Exoc4 sec8 SEC8
ZC168.6 ssp-34 Unknown MSP domain-containing protein ++
ZK546.2 Protein-protein interactionLeucine-rich repeat protein ++ LRRC57 Lrrc57 CG3040 CYR1
ZK593.6 lgg-2 Cell structure Microtubule-associated protein ++ MAP1LC3A Map1lc3a ATG8
ZK896.6 clec-187 Cell surface C-type lectin +++ MRC2 Mrc2
Genes were listed alphabetically by sequence name, followed by their locus, functional group, brief description, and suppression score. Hs, Mm, Dm,a n dSc refer to
human, mouse, fly, and yeast, respectively. Homologs were found by searching the Wormbase and NCBI databases. In some cases, sequences were aligned with
ClustalW to confirm assignments. The suppressor acr-7 (in bold) is homologous to a number of human a-like nAChRs.
doi:10.1371/journal.pgen.1003313.t001
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identified in acr-7 mutants [34].
Mutations in cha-1 or unc-17 failed to suppress
clozapine-induced larval arrest
Our results did not exclude the possibility that clozapine might
activate ACR-7 by triggering release of acetylcholine (Ach). If
clozapine does so, then mutations in genes required for Ach
release should have suppressed clozapine-induced developmental
delay. We tested two alleles of the choline acetyltransferase gene
cha-1 and two alleles of the synaptic vesicle Ach transporter gene
unc-17 for suppression of clozapine-induced developmental delay
[35,36]. Although both genes are required for Ach release, we
found that mutations in cha-1 or unc-17 were not suppressors,
suggesting that clozapine did not cause developmental delay by
stimulating Ach release (Figure 6).
acr-7 was expressed in pharyngeal muscle
We generated transgenic lines expressing a Pacr-7::GFP tran-
scriptional fusion construct or a Pacr-7::acr-7::GFP translational
fusion construct. In both cases, GFP was strongly expressed in the
pharyngeal muscles of transgenic animals (Figure 7A). Using
pharyngeal pumping and fluorescent bead assays, we previously
showed that clozapine caused dose-dependent inhibition of
pharyngeal pumping [12]. Inhibition of pharyngeal pumping
causes larval arrest in C. elegans [37]. Thus, clozapine likely delayed
development, in part, by inhibiting pharyngeal pumping.
What is the mechanism by which clozapine inhibited pharyn-
geal pumping? The C. elegans pharynx receives cholinergic
innervation from three types of pharyngeal motor neurons: M1,
M2, and M5 [38]. Nicotine inhibited pharyngeal pumping by
causing tetanic contraction of pharyngeal muscle [37]. Therefore,
we hypothesized that clozapine or the biologically active clozapine
metabolite N-desmethylclozapine [39] activated pharyngeal mus-
cle ACR-7 channels, causing tetanus with consequent larval arrest.
We further hypothesized that acr-7(tm863) and acr-7(RNAi) loss-of-
function mutations blocked activation by clozapine and thereby
suppressed pharyngeal paralysis and larval arrest.
Knockout of acr-7 suppressed clozapine-induced
inhibition of pharyngeal pumping
Clozapine inhibited pharyngeal pumping of wild-type animals
in a concentration-dependent manner. On average the pumping
rate in the absence of clozapine was 112.761.4 pumps/20 sec,
whereas the pumping rate in the presence of clozapine was
59.064.0 pumps/20 sec (160 mM), 34.463.7 pumps/20 sec
(320 mM), and 16.862.5 pumps/20 sec (500 mM) (Figure 7B,
P,0.0001, unpaired t-test). The pharyngeal pumping rate of acr-
7(tm863) mutants was slightly decreased compared to wild type.
The mean pumping rate of acr-7(tm863) mutants in the absence of
drug was 103.161.2 pumps/20 sec (Figure 7B, P,0.05, unpaired
t-test). That the acr-7(tm863) mutant displays a relatively normal
pumping rate argues against a model in which acr-7 is required for
pumping and clozapine inhibits this function. However, the acr-
7(tm863) deletion suppressed clozapine-induced inhibition of
pharyngeal pumping. While the mean pumping rate at 500 mM
clozapine was 16.862.5 pumps/20 sec for N2 animals, the rate for
acr-7(tm863) mutants was 40.962.9 pumps/20 sec (Figure 7B,
P,0.0001, unpaired t-test). Compared to acr-7(tm863) mutants,
acr-7(tm863) mchEx40 animals were partially rescued for this
Figure 2. Functional diversity of scla genes. Genes were classified by biological process based on Gene Ontology terms from Wormbase. The
percentages for each functional class of genes required for suppression of clozapine-induced larval arrest are shown.
doi:10.1371/journal.pgen.1003313.g002
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at 500 mM clozapine (Figure 7B, P,0.01, unpaired t-test).
In order to test whether ACR-7 acts specifically in pharyngeal
muscle to affect pumping, we generated transgenic lines expressing
Pmyo-2::acr-7 or Pmyo-2::acr-7::GFP translational fusion constructs.
myo-2 encodes a myosin heavy chain gene expressed exclusively in
pharyngeal muscle. acr-7(tm863) mchEx207 animals, expressing the
Pmyo-2::acr-7 transgene, were rescued for suppression of clozapine-
induced inhibition of pharyngeal pumping with a mean pumping
rate of 17.361.4 pumps/20 sec at 500 mM clozapine (Figure 7B,
P,0.001, unpaired t-test). acr-7(tm863) mchEx207 animals were
also rescued for suppression of clozapine-induced developmental
delay (Figure 4A). acr-7(tm863) mchEx211 animals, expressing the
Pmyo-2::acr-7::GFP transgene, displayed strong fluorescence in the
pharyngeal muscles and were rescued for both the pharyngeal
pumping and developmental phenotypes. Thus, acr-7 was required
in pharyngeal muscle for clozapine-induced inhibition of pharyn-
geal pumping and for clozapine-induced developmental delay.
Nicotine and levamisole phenocopied clozapine’s inhibition of
pharyngeal pumping. The mean pumping rate of N2 animals was
58.162.9 pumps/20 sec in 2 mM nicotine (Figure 7C, P,0.0001,
unpaired t-test) and 0.0 pumps/20 sec in 300 mM levamisole (data
Figure 3. ACR-7 protein sequence alignment and acr-7 gene structure. (A) The C. elegans ACR-7 protein and human a7-nAChR subunit
CHRNA7 were aligned using ClustalW. The four putative transmembrane domains, as predicted for the human CHRNA7 protein, were boxed. nAChRs
are members of the cys-loop family of ionotropic neurotransmitter receptors, and this conserved di-cysteine loop is dotted line-boxed. a-nAChR
subunits contain a pair of vicinal cysteines within the Ach binding site, and these residues are marked with asterisks. The C. elegans and human
proteins share 36% identity overall and 41% identity within the pore-lining transmembrane domain II (M2). (B) The acr-7 gene contains 13 exons, and
the region deleted in the tm863 allele is marked with a line. tm863 is an out-of-frame deletion which removes exons 6–7 and most of exons 5 and 8.
(C) The tm863 knockout is predicted to lack all four transmembrane domains and to be a null allele.
doi:10.1371/journal.pgen.1003313.g003
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type animals, similar to the relatively normal pharyngeal pumping
rate seen with acr-7 knockout. However, d-TC did block inhibition
of pharyngeal pumping by either clozapine or nicotine. The mean
pumping rate of wild-type animals in 500 mM clozapine was
25.363.1 pumps/20 sec (Figure 7C, P,0.0001, unpaired t-test),
compared to 69.564.9 pumps/20 sec with co-application of
500 mM d-TC (Figure 7C, P,0.0001, unpaired t-test). The mean
pumping rate of wild-type animals in 2 mM nicotine was
significantly increased to 68.563.7 pumps/20 sec with co-
application of 500 mM d-TC, compared to wild-type animals in
2 mM nicotine alone (Figure 7C, P,0.05, unpaired t-test).
However, d-TC failed to block the residual inhibition of
pharyngeal pumping produced by either clozapine or nicotine in
acr-7(tm863) mutants, indicating that acr-7 knockout occludes the
effect of d-TC (Figure 7D). These results suggested that clozapine
and nicotine inhibit pharyngeal pumping, in part, by activating
ACR-7 receptors in the pharynx.
Discussion
Clozapine exposure during adulthood modulates several C.
elegans behaviors, such as enhancement of egg-laying [11] and
inhibition of pharyngeal pumping [12,19] and locomotion. In
addition, clozapine exposure during early development produces
larval arrest in C. elegans [12,20], an effect that may relate to
human developmental abnormalities associated with clozapine
treatment during pregnancy [20,40]. High drug concentrations
Figure 4. Genetic and pharmacological characterization of clozapine-induced larval arrest. (A) Clozapine induced developmental delay in
wild-type C. elegans in a concentration-dependent manner. acr-7(tm863) partially suppressed this developmental delay, and the suppression was
rescued by expression of ACR-7 in the mutant background. Expression was driven by a putative acr-7 promoter in the case of acr-7(tm863) mchEx40
or by the pharyngeal muscle-specific myo-2 promoter in the case of acr-7(tm863) mchEx207. Growth was measured as the percentage of different
development stages 72 hours after loading synchronized L1 animals into the drug plates. Different concentrations (80, 160, 320 mM) of clozapine
were dissolved in DMSO with the maximum concentration of DMSO being 0.1%. 0.1% DMSO alone was used for control wells. (B) nAChR agonists
nicotine (Nico) and levamisole (Leva) induced developmental delay in a concentration-dependent manner, mimicking the effect of clozapine. (C)
Nicotine-induced developmental delay is suppressed by acr-7(tm863), and suppression was partially rescued by expression of full-length ACR-7 in the
mutant background. (D) Nicotine receptor antagonists d-TC (100 and 500 mM) and DHbE (100 and 500 mM) suppressed clozapine (Cloz)-induced
developmental delay. d-TC or DHbE alone did not affect the growth of the animals at 100 and 500 mM.
doi:10.1371/journal.pgen.1003313.g004
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used HPLC to show that clozapine levels required to produce
larval arrest in C. elegans (,18 mg/ml) [12] are close to those
expected in brains of human patients treated with clozapine
(,11 mg/ml) [42,43]. We employed clozapine-induced develop-
mental delay to perform a genome-wide RNAi screen in C. elegans
for scla genes and identified 40 candidate suppressors of clozapine-
induced larval arrest. Several suppressors, such as magi-1, lin-12,
Figure 5. Suppression by acr-7(lf) is specific. A series of 22 nAChR mutants were tested for suppression of clozapine-induced larval arrest, and
only acr-7(lf) produced robust suppression.
doi:10.1371/journal.pgen.1003313.g005
Figure 6. Ach release was not the mechanism of clozapine-induced larval arrest. Mutations in genes required for Ach release failed to
suppress clozapine-induced developmental delay. Strong loss-of-function of the choline acetyltransferase gene cha-1 or the synaptic vesicle Ach
transporter gene unc-17 alone produced developmental delay. Therefore, both weak (n2411 or e113) and strong (p1152 or e245) loss-of-function
alleles were tested.
doi:10.1371/journal.pgen.1003313.g006
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schizophrenia but have not been previously shown to mediate the
biological effects of an APD [44–46].
The molecular mechanisms of action of human disease genes
underlying psychotic disorders are largely unclear. The identifi-
cation of candidate APD targets in a genetic model organism with
a nervous system afforded us the opportunity to analyze the
mechanism of action of one such target in detail. However,
elucidating the mechanisms underlying APD modulation of ACR-
7 cannot fully explain the effects of APDs on C. elegans. Several
lines of evidence indicate that clozapine-induced larval arrest
involves multiple genetic pathways. First, the number and diversity
of suppressors to emerge from our screen suggest that they may
not constitute a single pathway. Second, clozapine’s developmen-
tal and behavioral effects in C. elegans are partially, not fully,
suppressed by acr-7(lf) (Figure 4A and Figure 7B). Third, other
pathways, such as the insulin signaling pathway, are known to be
involved [11,12,14]. Previously, we used a candidate gene
approach to show that mutations in the C. elegans insulin/IGF
receptor ortholog daf-2 and in its downstream effector the
phosphatidyl inositol 3-kinase (PI3K) age-1 suppressed clozapine-
induced larval arrest. Subsequent work confirmed the discovery
that clozapine activates insulin signaling in C. elegans and showed
that other APDs do so as well [13,14]. Of note, acr-7 and age-1 may
Figure 7. ACR-7 acted in the pharyngeal muscle. (A) ACR-7 was highly expressed in the pharynx as indicated by the arrows. A, anterior; P,
posterior; D, dorsal; V, ventral. Scattered expression was also observed in the tail and vulval regions. (B) Clozapine inhibited pharyngeal pumping in
wild-type animals in a concentration-dependent manner. Suppression of clozapine-induced inhibition of pharyngeal pumping was seen in acr-
7(tm863) animals, and rescue was observed with expression of ACR-7 in the mutant background. A putative acr-7 promoter was utilized to drive
expression for the acr-7(tm863) mchEx40 strain, whereas the pharyngeal muscle-specific myo-2 promoter was utilized for the acr-7(tm863) mchEx207
strain. (C) Both nicotine and clozapine inhibited the pumping rate in N2 animals. d-TC partially blocked these effects. Importantly, d-TC alone had no
effect on pumping. (D) d-TC failed to block clozapine- or nicotine-induced inhibition of pumping in acr-7(lf) animals. * P,0.05; ** P,0.01; ***
P,0.0001.
doi:10.1371/journal.pgen.1003313.g007
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nAChR has been shown to transduce signals to PI3K via direct
physical association in rat cortical cultures [47]. Fourth, clozapine
has moderate-to-high affinity for many neurotransmitter receptors,
and its complex pharmacology may well underlie its clinical
superiority. Indeed, ‘selectively non-selective’ drugs or ‘magic
shotguns’ with affinity for multiple specific targets with synergistic
effects may prove to be more effective medications for the
treatment of schizophrenia than selective drugs (‘magic bullets’)
that hit one target [5]. Therefore, it will be important to
understand not only how nAChR homologs might mediate
therapeutic or toxic effects of clozapine, but also how other
suppressors might do so. With this end in mind, detailed
characterization of several other suppressors is now underway in
our laboratory. These studies might provide evidence on how
different actions of clozapine interact.
We would also like to know whether particular suppressors
mediate clozapine-specific effects or mediate APD effects more
generally. To address the question of specificity will require
identifying the cellular and molecular mechanisms of suppression
for particular mutants and then testing the relevance of those
mechanisms for APDs other than clozapine. If the role of a
suppressor is clozapine-specific, that target may help explain
clozapine’s unique therapeutic or toxic effects. If the role is not
clozapine-specific, that target may help identify novel mechanisms
of action of APDs in general. Importantly then, further
characterization of suppressors from our screen may advance the
field whether suppression is a clozapine-specific effect or is a
characteristic of APDs in general.
Although some RNAi suppressors may act indirectly, some may
have human homologs that directly mediate either therapeutic or
toxic effects of clozapine. Based on the fact that cha-1(lf) and unc-
17(lf) alleles failed to suppress clozapine-induced larval arrest, we
hypothesized that clozapine does not stimulate Ach release, but
rather that clozapine modulates ACR-7 directly. Particularly in
whole-organism studies, direct effects can be pharmacologically
complex, involving activation, inhibition, or a combination of the
two. For instance, clozapine acts as an agonist at the human
muscarinic M1 receptor, while its biologically active metabolite, N-
desmethylclozapine, acts as an antagonist [39,48]. Such pharma-
cological complexity is relevant in the case of nAChRs specifically,
where, for example, addition of a methyl group at the amine
moiety of cocaine changes that drug’s profile from noncompetitive
antagonist to agonist [49]. To clarify the mechanism whereby
clozapine modulates ACR-7, we undertook a series of genetic,
pharmacological, developmental, and behavioral studies in C.
elegans.
We showed that that acr-7 mutants suppressed clozapine-
induced developmental delay and that a full-length translational
Pacr-7::acr-7::GFP fusion construct rescued this effect. acr-7 was
strongly expressed in the C. elegans pharynx, and acr-7 knockout
suppressed clozapine-induced inhibition of pharyngeal pumping.
Furthermore, a translational Pmyo-2::acr-7 fusion construct rescued
suppression of the developmental delay and pharyngeal pumping
phenotypes, indicating that ACR-7 acts specifically in pharyngeal
muscle cells to mediate these phenotypes. These results suggested
that clozapine activates ACR-7 to inhibit pharyngeal pumping
and, thereby, produce larval arrest. Consistent with this model,
nAChR agonists phenocopied both the developmental and
behavioral effects of clozapine. Similarly, nicotine-induced devel-
opmental delay required acr-7. However, acr-7(tm863) did not
block nicotine-induced inhibition of pharyngeal pumping, sug-
gesting that nicotine may act through multiple nAChRs to inhibit
pharyngeal pumping (Figure 7C and 7D).
Also consistent with our model, nAChR antagonists suppressed
clozapine-induced developmental delay and clozapine-induced
inhibition of pharyngeal pumping. The results indicated that, as
predicted on the basis of sequence information, acr-7 encodes a
nAChR. Suppression of the effects of nicotine and clozapine on
pharyngeal pumping and development are the first phenotypes to
be identified in acr-7 mutants [34]. As noted above, clozapine’s
effects at the whole-organism level may be pharmacologically
complex, involving activation, inhibition, or both, but the simplest
model to explain our results is that clozapine activates ACR-7.
Thus, our data pointed to a novel finding - the existence of
nAChRs that are activated by clozapine and/or the biologically
active clozapine metabolite N-desmethylclozapine [39].
A wealth of evidence has implicated nAChR expression and
function in general, and the a7-nAChR in particular, in the
pathogenesis of schizophrenia [15–17,50], a psychotic disorder for
which clozapine appears to be the most effective medication [2–4].
First, decreased nAChR expression has been reported in a number
of brain regions of schizophrenics [51–54]. Second, schizophrenics
smoke more frequently than the general population, and nicotine
exposure has been shown to improve cognition in animals and
humans. Therefore, increased smoking in schizophrenics may
represent an attempt to self-medicate for cognitive deficits
associated with the disease [50]. Third, genetic studies have linked
the human a7-nAChR gene (CHRNA7) to defective gating of the
P50 auditory evoked response, which is related to attentional
abnormalities in schizophrenia [17]. Finally, a7-nAChR agonists
are currently in development for the treatment of psychosis,
although no known APDs have been demonstrated to act by this
mechanism [16].
Previous reports have suggested that clozapine inhibits the
function of a7-nAChRs [55,56]. However, inhibition may be
specific to the background of the receptor or to species-specific
sequence differences [29,57,58]. Moreover, our RNAi screen was
designed to identify targets activated by clozapine, since we
screened for suppression of the drug’s effects by gene knockdown.
Interestingly, clozapine improved a schizophrenia-like endophe-
notype in mice via stimulation of a7-nAChRs, although this effect
was hypothesized to be indirect [59].
C. elegans has at least 29 different nAChR subunits grouped into
five subfamilies based on homology: DEG-3-like, UNC-38-like,
ACR-8-like, UNC-29-like, and ACR-16-like nAChRs [28,29].
ACR-7 is a member of the ACR-16-like group of nAChR
subunits, a group that shows homology to the vertebrate a7-10
nAChRs [28,29]. Importantly, we do not know which human a-
like subunit is the ACR-7 ortholog. For example, although acr-16
showed homology to the vertebrate a7-10 nAChRs, a mouse a4b2
nAChR transgene driven by the acr-16 promoter rescued nicotine-
dependent behaviors in the acr-16 mutant background, while a
mouse a7 nAChR transgene did not [60].
Mammals have at least 17 different nAChR subunits [28,30],
and these nAChRs may assemble in a wide variety of functional
combinations [31,61]. Of these, nine different a-nAChR subunits
have been cloned from mammalian tissues to date and have been
shown to form homopentamers or heteropentamers [30,61].
Effects of APDs on the spectrum of nAChR subunit combinations
have not been tested [62–65]. Therefore, whether APDs can
activate one or more of these receptors is an important question,
and finding such an interaction would constitute an important
breakthrough in APD drug development.
In summary, we conducted the first genetic suppressor screen
for APD targets in an animal. We then used the experimental
advantages of C. elegans neurobiology and neurogenetics to
delineate the novel molecular mechanism of action of a specific
C. elegans ACR-7 and Antipsychotic Drug Effects
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which clozapine may produce its therapeutic and/or toxic effects
in humans. This project was designed to translate basic findings in
C. elegans into clinical applications. Identification of new mecha-
nisms underlying the actions of APDs may lead to changes in both




We used the C. elegans Bristol strain N2 as the wild-type parent
of our mutant strains and grew nematodes under standard culture
conditions. Strains were maintained at 20uC. The mutant strains
used in our experiments are provided in Table S1. The age-
1(hx546) II mutation in strain TJ1052 had been backcrossed to the
N2 strain three times, and we performed another three backcrosses
to generate strain EAB100. The presence of the mutation was
followed by restriction digest and confirmed by DNA sequencing.
We backcrossed the following mutations to the N2 strain six times
to generate strains: EAB1 sms-1(ok2399) IV, EAB101 scla-
1(tm4806) IV, EAB102 scla-1(tm4534) IV, EAB103 ins-22(ok3616)
III, EAB200 acr-7(tm863) II, and EAB201 acr-16(ok789) V from
strains RB1854, F22B3.8(tm4806), F22B3.8(tm4534), RB2594,
FX863, and RB918, respectively. The presence of the deletions
was followed by PCR.
RNAi screen
We employed an RNAi feeding library (Geneservice Ltd),
constructed by J. Ahringer’s laboratory at the The Wellcome CRC
Institute, University of Cambridge, Cambridge, England, to carry
out a genome-wide screen in liquid culture for suppressors of
clozapine-induced larval arrest [21]. Our protocol for feeding
RNAi bacteria to animals in liquid culture was adapted from
Nollen et al. (2004) [66]. Each RNAi culture was grown overnight
at 37uC in 500 ml of LB with 100 mg/ml of ampicillin. The
cultures were induced for four hours the following day by adding
1 ml of LB containing 100 mg/ml ampicillin and 1 mM
isopropylthiogalactoside (IPTG) in a 37uC incubator. We trans-
ferred 200 ml of the induced cultures to 96-well plates and
centrifuged them at 3000 rpm for 2 minutes. The supernatant was
removed, and the induced bacterial pellet was resuspended in
100 ml of S-Basal. We then added 50 ml of solution containing S-
Basal, 50 mg/ml ampicillin, 1 mM IPTG, and ,3–5 synchronized
L1 rrf-3 animals. These animals were maintained in liquid culture
at 20uC on a rotating platform for three days until they reached
young adulthood. We then added 1.5 ml of clozapine stock
solution (20 mg/ml clozapine powder from Sigma-Aldrich
#C6305 in 100% ethanol) to each well for a final concentration
of 200 mg/ml (,600 mM) clozapine. Progeny were scored for
suppression of clozapine-induced larval arrest on day 8 (Figure 1A).
Wells containing progeny that had developed to the L4 stage or
beyond were scored as positives (Figure 1B). Those wells lacking
progeny or containing contamination were retested. Each set
included wells with dpy-6 RNAi in the absence of clozapine and
blank wells in the presence of clozapine as controls.
Positive wells from the genome-wide RNAi screen in liquid
culture were tested in triplicate using feeding RNAi on plates
containing Nematode Growth Medium (NGM). Each set included
triplicate wells of dpy-6 RNAi and unc-44 RNAi with and without
clozapine as controls. Those wells lacking progeny, lacking a lawn,
or containing contamination were retested. Mutants that produced
suppression in at least 2/3 wells were taken to be positives, and the
strength of suppression was scored: weak (+) - few progeny escaped
larval arrest, medium (++)-,25% of progeny escaped larval
arrest, robust (+++) - most progeny escaped larval arrest, NA - not
scored (Table 1). The identity of triplicate positives was verified by
sequencing plasmid DNA (MGH DNA Sequencing Core) using
primer M13 (Integrated DNA Technologies, Inc.) and then
blasting those sequences against the C. elegans genome using
Wormbase BLAT. Triplicate positives without preexisting gene
names and validated by knockout testing were assigned to the new
gene name class scla for Suppressor of Clozapine-induced Larval
Arrest.
Plasmid constructions
To generate a Pacr-7::GFP transcriptional fusion construct, we
PCR-amplified the putative promoter region, including 1.3-kb
upstream of the acr-7 gene, using DNA prepared from adult
animals and using primers listed in Table S2. This clone was
digested with PstI and XmaI restriction enzymes and ligated into
the GFP vector pPD95.75. To generate a Pacr-7::acr-7::GFP
translational fusion construct, we PCR-amplified the same acr-7
promoter sequence along with 4.3-kb of acr-7 genomic sequence,
omitting the native stop codon, using DNA prepared from adult
animals and using primers listed in Table S2. This clone was
digested with PstI and KpnI restriction enzymes, sub-electropo-
rated into pCR-XL-TOPO (Invitrogen, Cat: K4700-10), and then
subcloned into pPD95.75. PCR was performed using PrimeSTAR
HS DNA Polymerase (Takara Bio Inc.). GFP vector pPD95.75
was obtained from the Fire Lab C. elegans Vector Kit (Addgene).
To generate the Pmyo-2::acr-7 and Pmyo-2::acr-7::GFP transla-
tional fusion constructs, RNA was isolated from mixed-stage
worms, and acr-7 cDNA was obtained using SuperScript III First-
Strand Synthesis System (Invitrogen) with primers listed in Table
S2. We then cloned the cDNA into Fire Lab vectors L2531 or
L3790 (Addgene) using NheI and KpnI restriction enzymes or SalI
and EagI restriction enzymes respectively. These Pmyo-2 constructs
were injected into EAB200 animals using the same protocol
described below for injection of the Pacr-7::acr-7::GFP construct.
All plasmid constructions were confirmed by sequencing (MGH
DNA Sequencing Core).
Expression analysis
We generated extrachromosomal transgenic strains by micro-
injecting DNA into the gonads of young adult animals as described
[67]. The Pacr-7::GFP construct was injected at 25 ng/ml along
with the rol-6(su1006) marker (pRF4) at 50 ng/ml into N2 animals.
The Pacr-7::acr-7::GFP construct was injected at 25 ng/ml along
with the Pmyo-3::DsRed2 marker (pHC183; a gift from Antony Jose
of the Hunter laboratory) at 40 ng/ml into EAB200 animals.
Three to four independent extrachromosomal lines were gener-
ated for both the Pacr-7::GFP and Pacr-7::acr-7::GFP constructs.
ACR-7::GFP expression shown here was studied in the EAB40
strain, but similar results were obtained in studies of the EAB20 -
24, EAB39, and EAB41 strains. Animals were placed on a 2%
agarose pad on a slide in M9 with 50 mM sodium azide, then
covered with a slip and studied by DIC and fluorescence
microscopy using a Zeiss Axio Image A1 microscope. Photographs
were taken using a 406objective on a confocal laser microscope
(Leica TCS, Germany).
Developmental assays
Experiments were performed using Falcon 12-well plates
(Becton Dickinson) containing OP50 bacteria on NGM. Cloza-
pine, nicotine, levamisole, DHbE, and d-TC were purchased from
Sigma-Aldrich. Olanzapine was purchased from Waterstone
Technology. Stock solutions of each drug were prepared in
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(1:10,000). These diluted solutions were then pipetted onto the
agar surrounding the bacterial lawn for final drug concentrations
of 40, 80, 160, or 320 mM (0.1% DMSO), and the plates were left
to dry overnight. On the next day, ,30 synchronized L1 larvae
were loaded into each well. Animals were then scored as L1, L2,
L3, L4, young adult, or gravid adult at 24, 48, 72, 96 hours.
For stressor experiments, paraquat dichloride, tunicamycin, and
DL-Dithiothreitol (DTT) were purchased from Sigma-Aldrich,
and sodium dodecyl sulfate (SDS) was purchased from Fisher
Scientific. Stock solutions of 10% SDS, 2 M paraquat, or 0.2 M
DTT in water or 2.5 mg/ml tunicamycin in DMSO were diluted
in M9 and pipetted onto the agar to achieve a range of drug
concentrations. On the next day, 5–10 adult animals were placed
in each well of a 12-well plate. Adults were allowed to lay 25–50
eggs and then removed. Plates were scored for developmental
delay and lethality each day until the next generation hatched or
until all animals died.
Pharyngeal pumping assays
Drug plates were prepared as described above. Synchronized
L1 larvae were grown to the L4 stage and picked 24 hours in
advance of the experiments. Five adult animals were transferred
into drug wells or control wells (0.1% DMSO alone). Two hours
later, the number of pumps during 20 seconds was scored. Only
animals on the bacterial lawn were scored.
Statistical analysis
Data were expressed as means 6 S.E.M. Statistical comparisons
were performed using the unpaired, two-tailed Student’s t-test and
one-way ANOVA test where appropriate.
Supporting Information
Figure S1 RNAi screen mutants did not suppress stressor-
induced developmental delay. (A) Developmental delay seen with
SDS or paraquat after 24 hours. (B) Developmental delay seen
with SDS or paraquat after 48 hours. For control conditions,
vehicle alone was applied to the agar. Paraquat at 0.5 mM
produced significant lethality at 48 hours (data not shown).
(PDF)
Table S1 List of mutant strains used in these studies. Dr. L.
Chen (University of Minnesota, Minneapolis, MN) provided
LH202. Dr. C. Hunter (Harvard University, Cambridge, MA)
provided NL4256. Dr. Y. Jin (UCSD, La Jolla, CA) provided
CZ9957. Dr. S. Mitani (NBP-Japan) provided F22B3.8(tm4806) IV
and F22B3.8(tm4534) IV. All other strains used in this work, except
strains EAB1 through EAB211, were provided by the Caenorhabditis
Genetics Center, which is funded by the NIH National Center for
Research Resources (NCRR). NA, not available.
(PDF)
Table S2 List of primers used for plasmid constructions.
(PDF)
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